No Data
No Data
These four companies that are about to debut on the US stock market are worth focusing on. They may reverse the downturn in Biotech IPOs.
BioAge and Bicara hope to reverse the recent trend of obstacles in biotech companies' IPO in the US stock market; The binary nature of drug development has kept some investors away from the biotech industry.
Biotech Stocks Are Showing Signs of Life. Why the Rally Could Continue. -- Barrons.com
Morgan Stanley Stays Bullish on AI, Obesity, and Defense Focused Themes
Nvidia Earnings Will Affect ETFs, See 20 Funds That Traditionally Observe the Largest Moves
Healthcare Bankruptcies Slow After Peaking in 2023: Report
Small-cap and Mid-cap Health Care Has Room to Rally - Roth MKM